Literature DB >> 27672487

A Case of Treatment- resistant Depression and Body Dysmorphic Disorder: The Role of Electroconvulsive Therapy Revisited.

Ram S Mahato1, Maria Chona P San Gabriel1, Carrol T Longshore1, David B Schnur1.   

Abstract

Body dysmorphic disorder is a common, often disabling condition, and is frequently comorbid with major depressive disorder. Selective serotonin reuptake inhibitors constitute first line set of somatic interventions but the management of refractory patients remains challenging. Electroconvulsive therapy, an often highly beneficial treatment for medication resistant-depression, is not considered an effective therapeutic alternative for treatment refractory body dysmorphic disorder. Here we present a 50-year-old woman with body dysmorphic disorder and comorbid major depressive disorder who remained incapacitated and suicidal despite several trials with selective serotonin reuptake inhibitors and antipsychotic medication. Depressive and dysmorphic symptoms appeared to resolve with electroconvulsive therapy, and remission was sustained for two months. Electroconvulsive therapy has an important place in the management of treatment- resistant depression associated with body dysmorphic disorder, and, in select cases, may be effective for dysmorphic symptoms as well.

Entities:  

Keywords:  BDD; ECT; Electroconvulsive therapy; body dysmorphic disorder; depression; suicide attempt; treatmentresistant

Year:  2016        PMID: 27672487      PMCID: PMC5022988     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  23 in total

Review 1.  Dysmorphophobia: body dysmorphic disorder or delusional disorder, somatic subtype?

Authors:  J de Leon; A Bott; G M Simpson
Journal:  Compr Psychiatry       Date:  1989 Nov-Dec       Impact factor: 3.735

2.  A 12-month follow-up study of the course of body dysmorphic disorder.

Authors:  Katharine A Phillips; Maria E Pagano; William Menard; Robert L Stout
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

3.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.

Authors:  Michael Bauer; Andrea Pfennig; Emanuel Severus; Peter C Whybrow; Jules Angst; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2013-07-03       Impact factor: 4.132

4.  Clinical features and correlates of major depressive disorder in individuals with body dysmorphic disorder.

Authors:  Katharine A Phillips; Elizabeth R Didie; William Menard
Journal:  J Affect Disord       Date:  2006-08-07       Impact factor: 4.839

5.  Efficacy and safety of fluvoxamine in body dysmorphic disorder.

Authors:  K A Phillips; M M Dwight; S L McElroy
Journal:  J Clin Psychiatry       Date:  1998-04       Impact factor: 4.384

6.  Response of major depression with psychosis and body dysmorphic disorder to ECT.

Authors:  B J Carroll; R Yendrek; C Degroot; H Fanin
Journal:  Am J Psychiatry       Date:  1994-02       Impact factor: 18.112

7.  Dysmorphophobia or monosymptomatic hypochondriasis?

Authors:  C S Thomas
Journal:  Br J Psychiatry       Date:  1985-06       Impact factor: 9.319

8.  A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.

Authors:  Katharine A Phillips; Ralph S Albertini; Steven A Rasmussen
Journal:  Arch Gen Psychiatry       Date:  2002-04

9.  Body dysmorphic disorder: treating an underrecognized disorder.

Authors:  Katharine A Phillips; Elizabeth R Didie; Jamie Feusner; Sabine Wilhelm
Journal:  Am J Psychiatry       Date:  2008-09       Impact factor: 18.112

10.  Suicidality in body dysmorphic disorder: a prospective study.

Authors:  Katharine A Phillips; William Menard
Journal:  Am J Psychiatry       Date:  2006-07       Impact factor: 19.242

View more
  2 in total

Review 1.  Pharmacological Treatment of Body Dysmorphic Disorder.

Authors:  Kevin Hong; Vera Nezgovorova; Genoveva Uzunova; Danya Schlussel; Eric Hollander
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 2.  New perspectives in the treatment of body dysmorphic disorder.

Authors:  Kevin Hong; Vera Nezgovorova; Eric Hollander
Journal:  F1000Res       Date:  2018-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.